BCM
ANIK icon

Bayesian Capital Management’s Anika Therapeutics ANIK Stock Holding History

Bayesian Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,832
Closed -$613K – 768
2019
Q4 		$613K Buy
11,832
+7,300
+161% +$424K 0.1% 263
2019
Q3 		$249K Buy
+4,532
New +$233K 0.05% 406

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bayesian Capital Management's ANIK Position: Q1 2020 in Review

Bayesian Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 11,832 shares — an estimated $613K sold.

Bayesian Capital Management first reported a position in ANIK in Q3 2019 and held it in 2 quarters. The position peaked at $613K in Q4 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Bayesian Capital Management reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 11,832 Anika Therapeutics shares in Q1 2020, an estimated $613K.
  • Bayesian Capital Management first reported a position in Anika Therapeutics in Q3 2019 and held it in 2 quarters.
  • Bayesian Capital Management's Anika Therapeutics position peaked at $613K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Bayesian Capital Management's 13F filing for Q1 2020, filed 15 May 2020.